<DOC>
	<DOCNO>NCT00087217</DOCNO>
	<brief_summary>This phase I trial study side effect best dose 17-N-allylamino-17-demethoxygeldanamycin give together paclitaxel treat patient metastatic unresectable solid tumor . Drugs use chemotherapy , 17-N-allylamino-17-demethoxygeldanamycin paclitaxel , work different way stop tumor cell divide stop grow die . Combining 17-N-allylamino-17-demethoxygeldanamycin paclitaxel may kill tumor cell</brief_summary>
	<brief_title>17-N-Allylamino-17-Demethoxygeldanamycin Paclitaxel Treating Patients With Metastatic Unresectable Solid Tumor</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose recommended phase II dose 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) administer paclitaxel patient metastatic unresectable solid malignancy . II . Determine dose-limiting non-dose-limiting toxic effect regimen patient . III . Determine pharmacokinetics regimen patient . IV . Determine tumor response patient treat regimen . OUTLINE : This multicenter , dose-escalation study 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) . Patients receive 17-AAG IV 1 hour day 1* , 4 , 8 , 11 , 15 18 paclitaxel IV 1 hour day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . NOTE : *17-AAG administered day 1 course 1 . Cohorts 3-6 patient receive escalate dos 17-AAG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 6-12 patient treat recommended phase II dose .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm solid malignancy Metastatic unresectable disease Not amenable standard curative palliative therapy No known brain metastasis Performance status ECOG 02 More 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 AST ALT ≤ 2.5 time upper limit normal Bilirubin normal Creatinine normal Creatinine clearance ≥ 60 mL/min QTc &lt; 450 msec male patient ( 470 msec female patient ) LVEF &gt; 40 % MUGA No history serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No myocardial infarction within past year No New York Heart Association class III IV congestive heart failure No poorly control angina No history uncontrolled dysrhythmia requirement antiarrhythmic drug No history congenital long QT syndrome No active ischemic heart disease within past year No leave bundle branch block No significant cardiac disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective double barrier contraception least 1 week , , least 2 week study participation No prior allergy eggs No prior allergic reaction compound similar chemical biologic composition 17AAG paclitaxel No peripheral neuropathy &gt; grade 1 No concurrent uncontrolled illness No active ongoing infection No psychiatric illness social situation would preclude study compliance No concurrent granulocyte colonystimulating factor Prior paclitaxel allow More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior 17Nallylamino17demethoxygeldanamycin ( 17AAG ) More 4 week since prior radiotherapy No prior radiotherapy included heart field ( e.g. , mantle radiotherapy ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent therapeuticdose warfarin anticoagulation No concurrent medication may prolong QTc interval No concurrent investigational agent No concurrent anticancer agent therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>